Abu Dhabi Securities Exchange (ADX) Announces Issuing the First Sustainability Report During the First Half of 2020
ADX is participating in the "Second Abu Dhabi Sustainable Finance Forum" held under the umbrella of "Abu Dhabi Sustainability Week 2020", one of the world's most prominent sustainability events which takes place in the capital Abu Dhabi from 11th to 18th of January 2020.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200114005680/en/
H.E. Khalifa Salem Al Mansouri, Chief Executive of ADX (Photo: AETOSWire)
ADX is one of the signatories of the "Abu Dhabi Sustainable Finance Declaration", and a member of the "United Nations Sustainable Stock Exchange Initiative" (SSE). Today, Abu Dhabi Securities Exchange (ADX) announced that it will issue its first Environmental, Social & Governance (ESG) report in the first half of 2020. The report will be issued annually and is the first of its kind in the region.
The announcement comes few months after ADX issued a set of ESG disclosure guidelines to encourage listed companies to follow its lead and incorporate ESG issues into their business to test their effectiveness and act upon it. This will encourage listed companies to issue their sustainability reports, and it illustrates ADX’s commitment to drive sustainability in financial markets.
ADX is looking forward to an active participation in the discussions of the forum, which serves as an important opportunity to meet with different leaders around the world. ADX will discuss ways to integrate sustainability within the regulatory frameworks of investment institutions and cooperation with local and international sector leaders. This will enhance communication, knowledge and awareness in the field of sustainable financing, and will also help to explore Current and future opportunities for both sustainable finance and capital investment sectors, to obtain positive economic, social and environmental outcomes.
H.E. Khalifa Salem Al Mansouri, Chief Executive of ADX, said: “One of ADX’s strategic objectives is to advance Sustainable Development Goals (SDGs) through Sustainable Finance. Today I am proud to announce that ADX will release its first annual Environmental, Social & Governance (ESG) report in the first half of 2020. The report is instrumental in advancing our Sustainable Finance Agenda and promoting high sustainability standards. It also marks a significative step towards enhancing ADX's competitiveness and attracting more sustainable investments to Abu Dhabi.”
His Excellency continued: "In line with the growing investments made to companies that implements environmental, social and corporate governance, we aim to develop and position ADX as a vibrant and thriving sustainable investment hub that supports capital formation, raising and deployment as well as the creation and issuance of products to achieve positive economic, social and environmental objectives.”
His Excellency added: “Companies' commitments to developing strategies that integrate the standards of the report opens the way for investments supported by US$83 Trillion from various Asset Management Funds (AMC). These funds will be directed to companies that apply environmental, social and corporate governance standards. New Financial instruments and policies are among the instrumental components that will make up sustainable finance and ADX’s ESG report will encourage the business community to adopt practices that achieve environmental and social sustainability standards."
By adopting these high standards, ADX is in harmony with “Towards the next 50” that charts out the UAE’s strategic development plan which aims to build a sustainable, diversified and high value-added economy that positively contributes to transition to a new global sustainable development paradigm. ADX’s ESG report reinforces the guiding principles on Sustainable Finance and encourages building up investment opportunities while increasing the quality and depth of sustainable investments in the UAE.
About Abu Dhabi Securities Exchange:
Abu Dhabi Securities Exchange (ADX) was established on November 15 of the year 2000 by Local Law No. (3) Of 2000, the provisions of which vest the market with a legal entity of autonomous status, independent finance and management. The Law also provides ADX with the necessary supervisory and executive powers to exercise its functions.
ADX is a market for trading securities; including shares issued by public joint stock companies, bonds issued by governments or corporations, exchange traded funds, and any other financial instruments approved by the UAE Securities and Commodities Authority (SCA).
In 2014, ADX was upgraded to ‘Emerging Market’ status by both MSCI and S&P Dow Jones. ADX was already classified as an Emerging Market by FTSE in 2009 and in 2011 by S&P and Russell Investments.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20200114005680/en/
Contact information
Abu Dhabi Securities Exchange (ADX)
Abdulrahman Saleh ALKhateeb, Manager of Corporate Communication & Digital Marketing
Marketing & Corporate Communication Department
Tel: +97126128774
Mobile: +971506689733
Email: ALKhateebA@adx.ae
Newgate Communication
Habib Bacha
Tel: +97124420423
Mobile: +971501113799
Email: habib.bacha@newgatecomms.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Presents New Data Highlighting Scientific Advancements in Lung Cancer at ESMO Virtual Congress18.9.2020 13:55:00 EEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the company is presenting data from its lung cancer portfolio at the virtual European Society for Medical Oncology (ESMO) conference. Notably, insights from sub-analyses of the Phase 3 ALTA 1L study reinforce both the compelling evidence of intracranial efficacy with ALUNBRIG® (brigatinib) as a first-line treatment for patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) as well as associated quality of life (QoL) data. Takeda is also featuring updated 10-month follow-up results from the Phase 1/2 trial of mobocertinib (TAK-788), demonstrating mobocertinib achieved a duration of response (DoR) of more than one year in the trial’s study population of patients with epidermal growth factor receptor (EGFR) Exon20 insertion+ metastatic NSCLC (mNSCLC). “We’re pleased to present our ongoing research in lung cancer at this year’s virtual ESMO congress, including new
Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab (INCMGA0012) in Patients With Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal18.9.2020 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced results from its Phase 2 POD1UM-202 trial evaluating retifanlimab, a PD-1 inhibitor, in previously treated patients with advanced squamous cell carcinoma of the anal canal (SCAC) who have progressed following standard platinum-based chemotherapy. The trial enrolled 94 patients, including those with well-controlled human immunodeficiency virus (HIV) infection (10%). Retifanlimab monotherapy resulted in a confirmed objective response rate (ORR) of 14% as determined by independent central review (ICR) using RECIST v1.1. Responses were observed regardless of PD-L1 status, presence of liver metastases, age or HIV+ status. Retifanlimab was generally well-tolerated with a safety profile as expected of a PD-1 inhibitor and no loss of HIV infection control. Key findings from POD1UM-202: N=94 ORR* (95% CI) 13.8% (7.6-22.5) Best OR*, n 1 CR 12 PR 33 SD DCR 48.9% DOR, median (95% CI), months 9.5 (5.6-NE) PFS, median (95% CI), months 2.3 (1.9-3.6) OS, median (95
Sigfox and Cube Infrastructure Managers Announce Major Partnership in IoT Infrastructure18.9.2020 10:30:00 EEST | Press release
Sigfox, the global 0G network1 and cloud provider for industrial data, is proud to announce a new strategic alliance with Cube Infrastructure Managers (Cube), through the sale of its German 0G network to Cube. Sigfox has grown its 0G IoT services by rolling out 0G networks across 72 countries and regions, which was largely achieved with partners called Sigfox Operators. These operators are the owners of the 0G networks, which they operate as exclusive connectivity providers of Sigfox IoT services, offering worldwide connectivity to customers. The sale of the German network to Cube will allow Sigfox to finance its continued innovation efforts in data value extraction and improvements in cloud algorithms to reduce energy consumption and allow the implementation of even more cost-effective devices and sensors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200918005116/en/ Cube Infrastructure Managers, the European infrastructu
Sensorion successfully raises approximately €31 (US$ 36.5) million in an oversubscribed private placement to US and European investors18.9.2020 09:00:00 EEST | Press release
Regulatory News: Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia or Japan. This press release is not intended as an offer and is for informational purpose only Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN – the “Company”) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders announces today the success of its previously announced capital increase. The Company has placed 18,236,000 new ordinary shares with a nominal value of €0.10 each (the “New Shares”), for total gross proceeds of approximately € 31 million by means of an accelerated bookbuild offering to the benefit of categories of persons (the “Reserved Offering”). The issue price of the New Shares is €1.70 per share, representing a 3.5% discount to the weighted average share price on the day preceding the date on which the issuance price
ESMO 2020: Phase II CLARINET FORTE Results Show Increasing Dose Frequencies of Somatuline® Autogel® (lanreotide) Allows Patients with NETs to Delay Treatment Escalation by up to 8.3 Months18.9.2020 08:00:00 EEST | Press release
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the release of first efficacy and safety data from the CLARINET FORTE study, with the abstract to be presented as a mini-oral presentation at the 2020 European Society for Medical Oncology (ESMO) Congress, taking place virtually from 19-21 September 2020. The prospective single-arm, open-label, exploratory, international Phase II study investigated the efficacy and safety of increasing the dose frequency of Somatuline® Autogel ® (lanreotide) in patients with pancreatic or midgut NETs with centrally-assessed progression within the last two years while on a standard lanreotide regimen for ≥24 weeks. An extension of progression-free survival (PFS) rates and encouraging disease-control rates (DCR) were recorded in both tumor types, with no new safety signals. “These results support a clinically meaningful benefit to a population of patients with high unmet medical need by potentially delaying escalation to more toxic treatm
Vifor Pharma Group Announces Successful Sale of OM Pharma18.9.2020 08:00:00 EEST | Press release
Regulatory News: Vifor Pharma has today announced the successful sale of 100% of the share capital of OM Pharma, a Vifor Pharma Group company to Optimus Holding Ltd. The terms of the deal include: A purchase consideration of MCHF 435 for 100% of the share capital An earn out related to potential future value gains on 20% of Optimus Holding Ltd. equity to be determined before the end of 2027 upon a trade sale, IPO or EBITDA multiple This earn out together with the purchase consideration could result in a total transaction value exceeding MCHF 500. The deal is expected to close within 30 days. OM Pharma is a Geneva-based company mainly active in the field of microbial derived immunotherapeutics and has developed strongly outside the core strategy of Vifor Pharma over the past few years. Optimus Holding Ltd. is a Swiss Group, founded by Etienne Jornod together with long-standing Swiss entrepreneurs and Abdi Ibrahim (28.5%), a Turkey-based pharmaceutical company operating in 12 countries a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom